

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)

Taiji Sakamoto, Masahiko Shimura, Shigehiko Kitano, Masahito Ohji, Yuichiro Ogura, Hidetoshi Yamashita, Makoto Suzaki, Kimie Mori, Yohei Ohashi, Poh Sin Yap, Takeumi Kaneko, Tatsuro Ishibashi, for the MERCURY Study Group

Corresponding author:

Taiji Sakamoto

Department of Ophthalmology, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Tel: +81 99-275-5402

Fax: +81 99-265-4894

Email: tsakamot@m3.kufm.kagoshima-u.ac.jp

Online Resource 2. Study design

^aBaseline data collected within 2 months prior to ranibizumab injection was accepted.

^bWritten informed consent was required at or before Visit 1.

^cDME treatment was conducted by specialists according to individual patient requirements.

DME, diabetic macular oedema.

